Fasting Insulin and Risk of Cancer Related Mortality in Non-diabetic Adults: A Dose-response Meta-analysis of Cohort Studies

Author(s): Matin Ghanavati, Jamal Rahmani, Giulia Rinaldi, Hamid Zand*

Journal Name: Current Diabetes Reviews

Volume 16 , Issue 4 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Insulin is known to have direct and indirect effects on cell cycle progression, proliferation and metastatic activities. We performed a dose-response meta-analysis to investigate the association between hyperinsulinemia and all-cause cancer related mortality.

Methods: A systematic literature search was conducted on MEDLINE and SCOPUS databases to include all published articles up to January 2019. Combined hazard ratios (HRs) with 95% Confidence Intervals (CIs) were estimated using DerSimonian and Laird random-effects models. A dose-response analysis was also conducted to further explore insulin’s relationship with cancer-related mortality.

Results: We identified seven studies, with a total of 23,990 participants, who reported the association between hyperinsulinemia and cancer-related mortality. Results from the eligible studies indicated that higher fasting insulin levels were not associated with an increased risk of cancer mortality (pooled HR: 1.14, 95% CI: 0.99-1.32), however, significant heterogeneity was present (I2 = 60.3%, P heterogeneity = 0.001). A subgroup analysis based on gender demonstrated a significant association between fasting insulin level and cancer mortality in men (pooled HR: 1.92, 95% CI: 1.23-3.01, P heterogeneity = 0.281).

Conclusion: This dose-response meta-analysis showed a direct significant association between fasting insulin level and cancer mortality in men.

Keywords: Cancer, mortality, insulin, cohort, diabetes, fasting.

[1]
GBD 2016 Risk Factors Collaborators.Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390(10100): 1345-422.
[http://dx.doi.org/10.1016/S0140-6736(17)32366-8] [PMID: 28919119]
[2]
NCD Risk Factor Collaboration (NCD-RisC).Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387(10027): 1513-30.
[http://dx.doi.org/10.1016/S0140-6736(16)00618-8] [PMID: 27061677]
[3]
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7(2): 418-9.
[http://dx.doi.org/10.3945/an.116.012211] [PMID: 26980827]
[4]
Parekh N, Lin Y, Hayes RB, Albu JB, Lu-Yao GL. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 2010; 21(4): 631-42.
[http://dx.doi.org/10.1007/s10552-009-9492-y] [PMID: 20094767]
[5]
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159(12): 1160-7.
[http://dx.doi.org/10.1093/aje/kwh161] [PMID: 15191933]
[6]
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60(4): 207-21.
[http://dx.doi.org/10.3322/caac.20078] [PMID: 20554718]
[7]
Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131(11)(Suppl.): 3109S-20S.
[http://dx.doi.org/10.1093/jn/131.11.3109S] [PMID: 11694656]
[8]
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-9.
[http://dx.doi.org/10.1002/dmrr.912] [PMID: 19145584]
[9]
Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013; 20(1): R1-R17.
[http://dx.doi.org/10.1530/ERC-12-0324] [PMID: 23207292]
[10]
Leroith D, Scheinman EJ, Bitton-Worms K. The role of insulin and insulin-like growth factors in the increased risk of cancer in diabetes. Rambam Maimonides Med J 2011; 2(2)e0043
[http://dx.doi.org/10.5041/RMMJ.10043] [PMID: 23908801]
[11]
Denley A, Carroll JM, Brierley GV, et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007; 27(10): 3569-77.
[http://dx.doi.org/10.1128/MCB.01447-06] [PMID: 17325037]
[12]
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8(12): 915-28.
[http://dx.doi.org/10.1038/nrc2536] [PMID: 19029956]
[13]
Boyd DB. Insulin and cancer. Integr Cancer Ther 2003; 2(4): 315-29.
[http://dx.doi.org/10.1177/1534735403259152] [PMID: 14713323]
[14]
Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20(1): 42-51.
[http://dx.doi.org/10.1200/JCO.20.1.42] [PMID: 11773152]
[15]
Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A. Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care 2012; 35(7): 1538-43.
[http://dx.doi.org/10.2337/dc11-1513] [PMID: 22619079]
[16]
Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer 2017; 141(1): 102-11.
[http://dx.doi.org/10.1002/ijc.30729] [PMID: 28390156]
[17]
Wargny M, Balkau B, Lange C, Charles MA, Giral P, Simon D. Association of fasting serum insulin and cancer mortality in a healthy population - 28-year follow-up of the French TELECOM Study. Diabetes Metab 2018; 44(1): 30-7.
[http://dx.doi.org/10.1016/j.diabet.2017.03.006] [PMID: 28455114]
[18]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[19]
Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 2010; 29(12): 1282-97.
[http://dx.doi.org/10.1002/sim.3602] [PMID: 19408255]
[20]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[21]
Orsini N, Bellocco R. Greenland SJTsj. Generalized least squares for trend estimation of summarized dose–response data. Stata J 2006; 6(1): 40-57.
[http://dx.doi.org/10.1177/1536867X0600600103]
[22]
Balkau B, Kahn HS, Courbon D, Eschwège E, Ducimetière P. Paris Prospective Study.Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 2001; 24(5): 843-9.
[http://dx.doi.org/10.2337/diacare.24.5.843] [PMID: 11347741]
[23]
Perseghin G, Calori G, Lattuada G, et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 2012; 49(6): 421-8.
[http://dx.doi.org/10.1007/s00592-011-0361-2] [PMID: 22215126]
[24]
Borugian MJ, Sheps SB, Kim-Sing C, et al. Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 2004; 13(7): 1163-72.
[PMID: 15247127]
[25]
Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet 2012; 3: 268.
[http://dx.doi.org/10.3389/fgene.2012.00268] [PMID: 23226157]
[26]
Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010; 21(10): 610-8.
[http://dx.doi.org/10.1016/j.tem.2010.06.007] [PMID: 20663687]
[27]
Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119(2): 315-22.
[http://dx.doi.org/10.1172/JCI37432] [PMID: 19164855]
[28]
Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology 1980; 107(4): 1176-81.
[http://dx.doi.org/10.1210/endo-107-4-1176] [PMID: 6250795]
[29]
Chang Q, Li Y, White MF, Fletcher JA, Xiao S. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 2002; 62(21): 6035-8.
[PMID: 12414625]
[30]
Il’yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14(10): 2413-8.
[http://dx.doi.org/10.1158/1055-9965.EPI-05-0316] [PMID: 16214925]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2020
Page: [357 - 363]
Pages: 7
DOI: 10.2174/1573399815666190906130544
Price: $65

Article Metrics

PDF: 13
HTML: 1